Overview
Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2022-05-01
2022-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
the study is to evaluate the possible efficacy and safety of nitazoxanide as an adjuvant therapy in the secondary prevention of SBP in patient with cirrhosis.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Tanta UniversityTreatments:
Nitazoxanide
Norfloxacin
Criteria
Inclusion Criteria:- Patients aged 21 - 65 years old with cirrhosis and ascites who had at least one
previous confirmed episode of spontaneous bacterial peritonitis.
Exclusion Criteria:
- Exclusion criteria included active gastrointestinal bleeding Hepatic encephalopathy
(>grade 2) Hepatocellular carcinoma (HCC) or other malignancies Allergy to used
medications.